Cover Image
市場調查報告書

PharmaPoint:重度憂鬱症 - 美國的醫藥品的預測與市場分析

Major Depressive Disorder - US Drug Forecast and Market Assessment to 2025

出版商 GlobalData 商品編碼 305470
出版日期 內容資訊 英文 326 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:重度憂鬱症 - 美國的醫藥品的預測與市場分析 Major Depressive Disorder - US Drug Forecast and Market Assessment to 2025
出版日期: 2016年10月05日 內容資訊: 英文 326 Pages
簡介

重度憂鬱症是全球最常見的精神疾病之一。該市場的競爭激烈,有超過30種產品治療藥正在上市。在主要產品的專利到期、最終階段的開發平台產品投入市場的當下,市場正在大大變動中。美國雖然因為Cymbalta、Abilify、Seroquel XR等專利到期,市場暫時縮小,但一般預測之後從2018年後將會穩定成長。

本報告提供美國重度憂鬱症的治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要
  • 美國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌,選擇性血清素再吸收抑制劑
  • 產品簡介:領導品牌,血清素-去甲腎上腺素再吸收抑制劑
  • 產品簡介:領導品牌,其他抗憂鬱症藥
  • 產品簡介:領導品牌,抗精神藥
  • 其他的治療藥物分類

第6章 機會及未滿足需求

  • 概要
  • 更有效的藥物療法
  • 更良好的副作用簡介
  • 效果快速的抗憂鬱效果
  • 個人化醫療的方法

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 其他開發中的藥物

第8章 市場預測

  • 美國

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC375CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

GlobalData estimates that the MDD market will undergo a period of steady growth from 2015 to 2025, mainly attributed to the growth in atypical antipsychotics and the expected launch of five pipeline products.GlobalData anticipates that five products in the late-stage pipeline will enter the MDD market in the US during the forecast period: Alkermes' ALKS-5461, Allergan/Gedeon Richter/Mitsubishi Tanabe's Vraylar, Axsome Therapeutics' AXS-05, Janssen's esketamine, and Allergan's rapastinel.

Scope

  • Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US MDD market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for MDD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in the US.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Related Reports
  • 2.2 Upcoming Related Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder
  • 3.4 Prognosis
  • 3.5 Quality of Life

4 Disease Management

  • 4.1 Diagnosis and Treatment Overview
    • 4.1.1 Diagnosis
    • 4.1.2 Treatment Guidelines
    • 4.1.3 Clinical Practice
  • 4.2 US

5 Competitive Assessment

  • 5.1 Overview
  • 5.2 Selective Serotonin Reuptake Inhibitors
    • 5.2.1 Lexapro (Escitalopram)
    • 5.2.2 Viibryd (Vilazodone)
    • 5.2.3 Other Selective Serotonin Reuptake Inhibitors
  • 5.3 Serotonin-Norepinephrine Reuptake Inhibitors
    • 5.3.1 Cymbalta (Duloxetine)
    • 5.3.2 Effexor (Venlafaxine)
    • 5.3.3 Fetzima (Levomilnacipran)
    • 5.3.4 Savella (Milnacipran)
    • 5.3.5 Pristiq (Desvenlafaxine)
  • 5.4 Multimodal Antidepressants
    • 5.4.1 Trintellix (Vortioxetine)
  • 5.5 Other Antidepressants
    • 5.5.1 Bupropion
    • 5.5.2 Symbyax (Olanzapine/Fluoxetine)
    • 5.5.3 Mirtazapine
    • 5.5.4 Monoamine Oxidase Inhibitors
    • 5.5.5 Tricyclic Antidepressants
  • 5.6 Antipsychotics
    • 5.6.1 Abilify (Aripiprazole)
    • 5.6.2 Seroquel XR (Quetiapine XR)
    • 5.6.3 Rexulti (Brexpiprazole)
  • 5.7 Other Therapeutic Classes

6 Unmet Need and Opportunity

  • 6.1 Overview
  • 6.2 New Therapies with Better Efficacy
    • 6.2.1 Unmet Need
    • 6.2.2 Gap Analysis
    • 6.2.3 Opportunity
  • 6.3 Improved Safety Profiles
    • 6.3.1 Unmet Need
    • 6.3.2 Gap Analysis
    • 6.3.3 Opportunity
  • 6.4 Rapid Onset of Action
    • 6.4.1 Unmet Need
    • 6.4.2 Gap Analysis
    • 6.4.3 Opportunity
  • 6.5 Personalized Treatment Approach
    • 6.5.1 Unmet Need
    • 6.5.2 Gap Analysis
    • 6.5.3 Opportunity
  • 6.6 Manage Patient Outcome Expectations
    • 6.6.1 Unmet Need
    • 6.6.2 Gap Analysis
    • 6.6.3 Opportunity

7 Pipeline Assessment

  • 7.1 Overview
  • 7.2 Clinical Trial Mapping
    • 7.2.1 Clinical Trials by Class of Therapy
  • 7.3 Promising Drugs in Clinical Development
    • 7.3.1 ALKS-5461
    • 7.3.2 Vraylar (Cariprazine)
    • 7.3.3 ASC-01
    • 7.3.4 AXS-05
    • 7.3.5 Esketamine
    • 7.3.6 Rapastinel (GLYX-13)
    • 7.3.7 Strada (MSI-195)
    • 7.3.8 Viotra (Tramadol)
  • 7.4 Promising Drugs in Early-Stage Development
    • 7.4.1 CGP3466B
    • 7.4.2 NSI-189
  • 7.5 Other Drugs in Development

8 Market Outlook

  • 8.1 US
    • 8.1.1 Forecast
    • 8.1.2 Key Events
    • 8.1.3 Drivers and Barriers

9 Appendix

  • 9.1 Bibliography
  • 9.2 Abbreviations
  • 9.3 Methodology
  • 9.4 Forecasting Methodology
    • 9.4.1 Diagnosed NSCLC Patients
    • 9.4.2 Percent Drug-Treated Patients
    • 9.4.3 Drugs Included in Each Therapeutic Class
    • 9.4.4 Launch and Patent Expiry Dates
    • 9.4.5 General Pricing Assumptions
    • 9.4.6 Individual Drug Assumptions
    • 9.4.7 Generic Erosion
    • 9.4.8 Pricing of Pipeline Agents
  • 9.5 Primary Research - KOLs
    • 9.5.1 KOLs
  • 9.6 About the Authors
    • 9.6.1 Analyst
    • 9.6.2 Therapy Area Director
    • 9.6.3 Epidemiologist
    • 9.6.4 Global Head of Healthcare
  • 9.7 About GlobalData
  • 9.8 Disclaimer

List of Tables

  • Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015
  • Table 6: Country Profile - US
  • Table 7: Leading Treatments for MDD, 2016
  • Table 8: Product Profile - Lexapro
  • Table 9: Lexapro/Cipralex SWOT Analysis, 2016
  • Table 10: Product Profile - Viibryd
  • Table 11: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials
  • Table 12: Viibryd SWOT Analysis, 2016
  • Table 13: Summary of SSRIs, 2016
  • Table 14: SSRIs SWOT Analysis, 2016
  • Table 15: Product Profile - Cymbalta
  • Table 16: Cymbalta SWOT Analysis, 2016
  • Table 17: Product Profile - Effexor
  • Table 18: Effexor SWOT Analysis, 2016
  • Table 19: Product Profile - Fetzima
  • Table 20: Fetzima SWOT Analysis, 2016
  • Table 21: Product Profile - Savella
  • Table 22: Savella SWOT Analysis, 2016
  • Table 23: Product Profile - Pristiq
  • Table 24: Pristiq SWOT Analysis, 2016
  • Table 25: Product Profile - Trintellix
  • Table 26: Trintellix SWOT Analysis, 2016
  • Table 27: Product Profile - Bupropion
  • Table 28: Bupropion SWOT Analysis, 2016
  • Table 29: Product Profile - Symbyax
  • Table 30: Symbyax SWOT Analysis, 2016
  • Table 31: Product Profile - Mirtazapine
  • Table 32: Mirtazapine SWOT Analysis, 2016
  • Table 33: MAOIs SWOT Analysis, 2016
  • Table 34: TCAs SWOT Analysis, 2016
  • Table 35: Product Profile - Abilify
  • Table 36: Abilify SWOT Analysis, 2016
  • Table 37: Product Profile - Seroquel XR
  • Table 38: Seroquel XR SWOT Analysis, 2016
  • Table 39: Product Profile - Rexulti
  • Table 40: Rexulti SWOT Analysis, 2016
  • Table 41: Summary of Minor Therapeutic Classes in MDD, 2016
  • Table 42: Unmet Needs and Opportunities in MDD
  • Table 43: Promising Drugs in Clinical Development for MDD, 2016
  • Table 44: Comparison of Drugs in Development for MDD, 2016
  • Table 45: Product Profile - ALKS-5461
  • Table 46: SWOT Analysis - ALKS-5461, 2016
  • Table 47: Product Profile - Vraylar
  • Table 48: SWOT Analysis - Vraylar, 2016
  • Table 49: Product Profile - ASC-01
  • Table 50: SWOT Analysis - ASC-01, 2016
  • Table 51: Product Profile - AXS-05
  • Table 52: SWOT Analysis - AXS-05, 2016
  • Table 53: Product Profile - Esketamine
  • Table 54: SWOT Analysis - Esketamine, 2016
  • Table 55: Product Profile - Rapastinel
  • Table 56: SWOT Analysis - Rapastinel, 2016
  • Table 57: Product Profile - Strada
  • Table 58: SWOT Analysis - Strada, 2016
  • Table 59: Product Profile - Viotra
  • Table 60: SWOT Analysis - Viotra, 2015
  • Table 61: Drugs in Development, 2016
  • Table 62: Key Events Impacting Sales for MDD Therapies in the US, 2015-2025
  • Table 63: MDD Market - Drivers and Barriers in the US, 2015-2025
  • Table 64: Key Launch Dates - Part I
  • Table 65: Key Launch Dates - Part II
  • Table 66: Key Patent Expiries

Table 67 Average Body Weight and Surface Area Across the 8MM 298

  • Table 68: Average Cost of Therapy of Alimta in the 8MM
  • Table 69: Average Cost of Therapy of Alecensa in the 8MM
  • Table 70: Average Cost of Therapy of Avastin
  • Table 71: Average Cost of Therapy of Cyramza
  • Table 72: Average Cost of Therapy of Gilotrif
  • Table 73: Average Cost of Therapy of Iressa
  • Table 74: Average Cost of Therapy of Portrazza
  • Table 75: Average Cost of Therapy of Tagrisso
  • Table 76: Average Cost of Therapy of Tarceva
  • Table 77: Average Cost of Therapy of Vargatef
  • Table 78: Average Cost of Therapy of Xalkori
  • Table 79: Average Cost of Therapy of Zykadia
  • Table 80: Average Cost of Therapy of Keytruda
  • Table 81: Average Cost of Therapy of Opdivo
  • Table 82: Average Cost of Therapy of Tecentriq
  • Table 83: Average Cost of Therapy of Conmana
  • Table 84: High-Prescribing Physicians Surveyed by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016
  • Figure 5: MDD Phase II/Phase III Pipeline, 2016
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025
  • Figure 7: Clinical and Commercial Positioning of ALKS-5461
  • Figure 8: Clinical and Commercial Positioning of Vraylar
  • Figure 9: Clinical and Commercial Positioning of ASC-01
  • Figure 10: Clinical and Commercial Positioning of AXS-05
  • Figure 11: Clinical and Commercial Positioning of Esketamine
  • Figure 12: Clinical and Commercial Positioning of Rapastinel
  • Figure 13: Clinical and Commercial Positioning of Strada
  • Figure 14: Clinical and Commercial Positioning of Viotra
  • Figure 15: US Sales by Drug Class for MDD Therapies, 2015 and 2025
  • Figure 16: US Sales by Drug Class for MDD Therapies, 2015-2025
Back to Top